Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 9/20 | 0.86 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 2/20 | 0.33 |
| ▸ | RXRB | P28702 | 2/20 | 0.33 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL803396 | 0.93 | S1PR3 (1.00) | S1PR3PDE10ATDP1CNR1GPR84 | |
| SCHEMBL2834033 | 0.85 | S1PR3 (0.76) | S1PR3PDE10A | |
| SCHEMBL2834036 | 0.85 | S1PR3 (0.74) | S1PR3PDE10ACNR1LTB4R | |
| SCHEMBL803571 | 0.82 | S1PR3 (1.00) | S1PR3PDE10AGPR84 | |
| SCHEMBL14272852 | 0.81 | S1PR3 (0.86) | S1PR3TDP1CNR1 | |
| SCHEMBL802972 | 0.81 | S1PR3 (0.85) | S1PR3PDE10A | |
| SCHEMBL2836970 | 0.76 | S1PR3 (0.78) | S1PR3PDE10A | |
| SCHEMBL2836971 | 0.76 | S1PR3 (0.76) | S1PR3PDE10A | |
| SCHEMBL2834796 | 0.75 | S1PR3 (0.67) | S1PR3 | |
| SCHEMBL2829623 | 0.73 | S1PR3 (0.57) | S1PR3PDE10ATDP1RXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071448-A1 | S1P3 Receptor Inhibitors for Treating Conditions of the Eye | ALLERGAN, INC. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071448-A1 | S1P3 Receptor Inhibitors for Treating Conditions of the Eye | S1PR3, S1PR1, S1PR2 | S1PR3 1/4885PDE10A 1000/4885TDP1 3381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.